Tempest Therapeutics, Inc. — Director's Dealing 2018

Dec 12, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Millendo Therapeutics, Inc. (MLND)
CIK: 0001544227
Period of Report: 2018-12-07

Reporting Person: WHITCOMB RANDALL W (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-12-07	Common Stock	A	15784	—	Acquired	15784	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-12-07	Stock Option (right to buy)	$4.44	A	21438	Acquired	2026-01-27	Common Stock (21438)	Direct
2018-12-07	Stock Option (right to buy)	$16.40	A	3720	Acquired	2028-08-23	Common Stock (3720)	Direct

Footnotes

F1: Received in exchange for 212,163 shares of Millendo Therapeutics, Inc. ("Millendo") common stock in connection with merger of Millendo Therapeutics, Inc. into the Issuer (the "Merger").

F2: Twenty-five percent (25%) of the shares subject to the option vested on January 28, 2017, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.

F3: Received in connection with the Merger in exchange for a stock option to acquire 288,152 shares of Millendo common stock for $0.33 per share.

F4: Twenty-five percent (25%) of the shares subject to the option shall vest on August 20, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.

F5: Received in connection with the Merger in exchange for a stock option to acquire 50,000 shares of Millendo common stock for $1.22 per share.